Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis.
Int J Biol Macromol
; 95: 263-267, 2017 Feb.
Article
em En
| MEDLINE
| ID: mdl-27876598
ABSTRACT
BACKGROUND:
Snake venoms are great sources of bioactive molecules, which may be used as models for new drugs. Toxins that interfere in hemostasis have received considerable attention over the years.OBJECTIVES:
This study aimed at the evaluation of the antithrombotic activity of Batroxase, a P-I metalloprotease from Bothrops atrox venom, in an animal model of venous thrombosis.METHODS:
The antithrombotic activity of Batroxase was tested in vivo in a model based on two factors of the Virchow's Triad blood flow alterations (partial stenosis of the inferior vena cava), and vessel wall injury (10% ferric chloride for 5min), in comparison with sodium heparin (positive control) and saline (negative control). Bleeding/clotting time was assessed by a tail bleeding assay. The immunogenicity of Batroxase was also analyzed.RESULTS:
Batroxase (12mg/kg) reduced thrombus formation in 81%, similarly to heparin (100U/kg), which reduced it in 85% in comparison with the saline group. Both Batroxase and heparin increased bleeding/clotting time in approximately 3 fold. Immunizations of rabbits with Batroxase do not result in detectable levels of antibodies against this metalloprotease.CONCLUSION:
Batroxase presents antithrombotic activity in vivo. Moreover, its lack of immunogenicity increases the interest on its possible therapeutic potential over thrombogenic disorders.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Bothrops
/
Trombose Venosa
/
Venenos de Crotalídeos
/
Metaloproteases
/
Fibrinolíticos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Int J Biol Macromol
Ano de publicação:
2017
Tipo de documento:
Article